Developer docs
API playgroundTry for free, no card

Search company profiles

Disc Medicine

Full company profile

uuid00008e4

Namestring
Disc Medicine
Legal namestring
Disc Medicine, Inc.
Company typeenum
Public
Founded yearint
2022
Descriptiontext

Disc Medicine is a clinical-stage biopharmaceutical company developing therapies for hematologic diseases and rare blood disorders. Founded in 2017 and headquartered in Watertown, Massachusetts, the company is publicly traded on NASDAQ under the ticker IRON after a 2022 reverse merger with Gemini Therapeutics. The company applies two core biological mechanisms across its pipeline: heme biosynthesis modulation via the GlyT1 inhibitor bitopertin, originally licensed from Roche, and hepcidin pathway modulation via anti-hemojuvelin antibody DISC-0974 (AbbVie/Mabwell-licensed) and anti-TMPRSS6 siRNA DISC-3405 (Kyowa Kirin-licensed). Lead candidate bitopertin is in Phase 3 for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Phase 2 for Diamond-Blackfan anemia (DBA). DISC-0974 is in Phase 1/2 development for anemia in myelofibrosis, inflammatory bowel disease, and chronic kidney disease. DISC-3405 is in Phase 2 for polycythemia vera and Phase 1 for sickle cell disease. The company has no commercialized products, no recurring revenue, and is funded entirely through equity capital, with approximately $730M in cash and equivalents following an October 2025 $250M public offering, providing runway into 2029.

The company's business model is conventional clinical-stage biopharma: it advances in-licensed or internally-discovered therapeutic candidates through clinical trials toward regulatory approval, with the intent of either commercializing independently via a specialty sales force in the rare disease space, or partnering ex-U.S. rights to a larger pharmaceutical company. Disc Medicine was actively building pre-commercial capabilities, including medical science liaison deployment and field force expansion, in advance of a planned bitopertin launch in EPP. In February 2026, the FDA issued a Complete Response Letter for the bitopertin NDA, leading the company to announce a 20% workforce reduction, pausing of certain pipeline programs (DISC-3405 in CKD anemia, narrowing of DISC-0974), and securities litigation. A June 2026 Type A meeting with the FDA aligned on a path to resubmit the bitopertin NDA using existing Phase 3 APOLLO data, restoring a clearer regulatory pathway. Target customer segments are highly concentrated specialty hematology prescribers, genetic disease specialists, and rare disease patients identified through specialized treatment centers in the U.S., with potential ex-U.S. commercialization via partnership.

Short descriptiontext

Disc Medicine is a clinical-stage biopharmaceutical company developing small-molecule and biologic therapies for rare hematologic diseases, including erythropoietic protoporphyria, polycythemia vera, and sickle cell disease, targeting specialty hematology prescribers and rare disease patient populations.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersWatertown, United States
HQ citystring
Watertown
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
hematology therapeutics, rare blood disorders, biopharmaceutical drug development, hepcidin pathway modulation, heme biosynthesis inhibitors
Industry4 codes
PRIMARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIAIAC
Rare Oncology & Hematologic Malignancy Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAH
Rare Cardiovascular & Vascular Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAJ
Rare Endocrine & Growth Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Rare Hematology Biopharmaceuticals
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Pre-Revenue / Clinical Stage
TypeSubscription Recurring
Description

Disc Medicine is pre-revenue. The company reported a loss of $241.60m with no revenue as of mid-2026. Net loss for FY2025 was $212.2M (vs. $109.4M in 2024) and Q1 2026 net loss was $63.5M (vs. $34.1M in Q1 2025). Future revenue expected from drug commercialization if/when approved.

simplywall.st
2Future Drug Commercialization (Planned)
TypeHardware Sales
Description

Intends to use $250M October 2025 offering proceeds to support potential commercialization of its drug for hematologic diseases. Expected future revenue model would be standard biopharma drug sales / specialty pharma commercialization targeting rare disease populations.

ir.discmedicine.com
3Bitopertin In-Licensing from Roche
TypeLicensing Royalties
Description

Bitopertin was in-licensed from Roche in May 2021. Disc obtained global rights to develop and commercialize bitopertin, with Roche receiving milestone and royalty entitlements (financial structure not publicly disclosed in detail).

Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Others
Pricing details1 tier
1Not applicable — pre-revenue, clinical-stage company with no approved products.
ModelOther
Notes

No pricing information publicly available. Company is pre-commercial; pricing for any approved drug (e.g., bitopertin for EPP/XLP) would be set at or after launch.

simplywall.st
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Disc Medicine is a clinical-stage biopharmaceutical company developing investigational therapies for hematologic diseases and rare blood disorders. The company's pipeline targets two core biological processes: heme biosynthesis modulation and hepcidin pathway modulation (both suppression and induction). Lead assets include bitopertin (oral GlyT1 inhibitor for EPP/XLP), DISC-0974 (anti-HJV antibody for anemia of inflammation), DISC-3405 (anti-TMPRSS6 antibody for iron overload disorders), and DISC-0998 (preclinical anti-HJV). The company is pre-revenue with no approved products on the market.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 55-64% major response rates in myelofibrosis patients across subgroups in DISC-0974 RALLY-MF Phase 2 trial
+3 more records
Product overview1 text field

Disc Medicine is a clinical-stage biopharmaceutical company developing therapeutics for hematologic diseases. No detailed product/module breakdown is supported by properly attributed source data.

Product and service5 records
1Bitopertin
CategoryHematology Biopharmaceuticals — Heme Biosynthesis Modulators
Description

Oral selective inhibitor of glycine transporter 1 (GlyT1) that limits glycine uptake into developing red blood cells, regulating downstream heme biosynthesis and reducing toxic protoporphyrin IX (PPIX) accumulation. In-licensed from Roche and being developed for EPP, XLP, and DBA. Currently in Phase 3 APOLLO trial (183 participants across US, Canada, Europe, Australia), with topline data expected Q4 2026 and potential FDA decision anticipated by mid-2027 following the February 2026 Complete Response Letter.

2DISC-0974
CategoryHematology Biopharmaceuticals — Hepcidin Suppression (Anti-HJV Antibodies)
Description

Anti-hemojuvelin (HJV) monoclonal antibody that binds HJV to suppress hepcidin expression, enhancing iron availability for erythropoiesis to treat anemia of inflammation. In-licensed from AbbVie. Phase 2 RALLY-MF trial reported 70% overall response rate with 54-67% major response rates across evaluable cohorts in myelofibrosis patients.

3DISC-3405
CategoryHematology Biopharmaceuticals — Hepcidin Induction (Anti-TMPRSS6 Antibodies)
Description

Recombinant humanized monoclonal antibody targeting TMPRSS6 (Matriptase-2) to induce endogenous hepcidin expression, reducing iron levels for diseases enabled by iron availability. Mechanism validated by human genetics (IRIDA patients with TMPRSS6 mutations). In-licensed from Mabwell. Holds FDA Fast Track Designation for polycythemia vera (PV).

4DISC-0998
5Bitopertin Expanded Access Program (EAP)
CategoryPatient Access Programs
Description

Expanded Access Program providing investigational bitopertin to eligible EPP/XLP patients who lack satisfactory therapeutic alternatives. Listed on ClinicalTrials.gov (NCT07603401) and accessible via bitopertinEAP@discmedicine.com. Functions as the current pre-approval access pathway for the lead asset.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-08-10
Description

Gemini Therapeutics announced plans to merge with Disc Medicine in August 2022, as part of Gemini's strategic restructuring efforts. The merger brought together Gemini's ocular/age-related macular degeneration program with Disc's hematology pipeline; Georges Gemayel (former Executive Chair of Gemini Therapeutics) now serves on Disc Medicine's Board of Directors.

Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2021-05-01
Description

Bitopertin (GlyT1 inhibitor) was in-licensed from Roche in May 2021, with Disc obtaining global rights to develop and commercialize the asset for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) and other conditions associated with abnormal erythropoiesis. Bitopertin was previously studied in over 4,000 participants across other indications, providing extensive safety characterization.

Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing Partner
Description

DISC-0974 (anti-hemojuvelin monoclonal antibody for anemia of inflammation) and DISC-0998 (extended half-life anti-HJV antibody) were in-licensed from AbbVie. Disc has advanced DISC-0974 into multiple Phase 1b/2 and Phase 2 studies in myelofibrosis, inflammatory bowel disease, and chronic kidney disease.

Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing Partner
Description

DISC-3405 (anti-TMPRSS6 monoclonal antibody, formerly MWTX-003) was in-licensed from Mabwell Therapeutics. Mabwell (Shanghai) Bioscience Co., Ltd. holds international licensing partnership with Disc worth up to US$412.5 million. Phase 1 healthy volunteer study completed; Phase 2 PV (FDA Fast Track) and Phase 1b SCD studies initiated.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Investigator-initiated trial with NIH for bitopertin in Diamond Blackfan Anemia (DBA), a rare congenital bone marrow failure syndrome. This is a Phase 2 study leveraging the bitopertin mechanism for heme modulation in a second indication.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors20 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Disc Medicine

Rare Hematology Biopharmaceuticalsdiscmedicine.com

Disc Medicine is a clinical-stage biopharmaceutical company developing small-molecule and biologic therapies for rare hematologic diseases, including erythropoietic protoporphyria, polycythemia vera, and sickle cell disease, targeting specialty hematology prescribers and rare disease patient populations.

What Disc Medicine does

Disc Medicine is a clinical-stage biopharmaceutical company developing therapies for hematologic diseases and rare blood disorders. Founded in 2017 and headquartered in Watertown, Massachusetts, the company is publicly traded on NASDAQ under the ticker IRON after a 2022 reverse merger with Gemini Therapeutics. The company applies two core biological mechanisms across its pipeline: heme biosynthesis modulation via the GlyT1 inhibitor bitopertin, originally licensed from Roche, and hepcidin pathway modulation via anti-hemojuvelin antibody DISC-0974 (AbbVie/Mabwell-licensed) and anti-TMPRSS6 siRNA DISC-3405 (Kyowa Kirin-licensed). Lead candidate bitopertin is in Phase 3 for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Phase 2 for Diamond-Blackfan anemia (DBA). DISC-0974 is in Phase 1/2 development for anemia in myelofibrosis, inflammatory bowel disease, and chronic kidney disease. DISC-3405 is in Phase 2 for polycythemia vera and Phase 1 for sickle cell disease. The company has no commercialized products, no recurring revenue, and is funded entirely through equity capital, with approximately $730M in cash and equivalents following an October 2025 $250M public offering, providing runway into 2029.

The company's business model is conventional clinical-stage biopharma: it advances in-licensed or internally-discovered therapeutic candidates through clinical trials toward regulatory approval, with the intent of either commercializing independently via a specialty sales force in the rare disease space, or partnering ex-U.S. rights to a larger pharmaceutical company. Disc Medicine was actively building pre-commercial capabilities, including medical science liaison deployment and field force expansion, in advance of a planned bitopertin launch in EPP. In February 2026, the FDA issued a Complete Response Letter for the bitopertin NDA, leading the company to announce a 20% workforce reduction, pausing of certain pipeline programs (DISC-3405 in CKD anemia, narrowing of DISC-0974), and securities litigation. A June 2026 Type A meeting with the FDA aligned on a path to resubmit the bitopertin NDA using existing Phase 3 APOLLO data, restoring a clearer regulatory pathway. Target customer segments are highly concentrated specialty hematology prescribers, genetic disease specialists, and rare disease patients identified through specialized treatment centers in the U.S., with potential ex-U.S. commercialization via partnership.

Disc Medicine firmographics

Firmographics
Name
Disc Medicine
Legal name
Disc Medicine, Inc.
Website
https://discmedicine.com
Company type
Public
Founded year
2022
Operating status
Operating
Headcount range
101–250 employees
Short description
Disc Medicine is a clinical-stage biopharmaceutical company developing small-molecule and biologic therapies for rare hematologic diseases, including erythropoietic protoporphyria, polycythemia vera, and sickle cell disease, targeting specialty hematology prescribers and rare disease patient populations.
Ownership category
akta.pro rank

Disc Medicine industry classification

Industry
Product category
Rare Hematology Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIAIAC
Rare Oncology & Hematologic Malignancy Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAH
Rare Cardiovascular & Vascular Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAJ
Rare Endocrine & Growth Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Hematology therapeutics
  • Rare blood disorders
  • Biopharmaceutical drug development
  • Hepcidin pathway modulation
  • Heme biosynthesis inhibitors

Where Disc Medicine is headquartered

Location

Headquarters

HQ city
Watertown
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Disc Medicine business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Others

Revenue model

  1. Pre-Revenue / Clinical Stage: Disc Medicine is pre-revenue. The company reported a loss of $241.60m with no revenue as of mid-2026. Net loss for FY2025 was $212.2M (vs. $109.4M in 2024) and Q1 2026 net loss was $63.5M (vs. $34.1M in Q1 2025). Future revenue expected from drug commercialization if/when approved.
  2. Future Drug Commercialization (Planned): Intends to use $250M October 2025 offering proceeds to support potential commercialization of its drug for hematologic diseases. Expected future revenue model would be standard biopharma drug sales / specialty pharma commercialization targeting rare disease populations.
  3. Bitopertin In-Licensing from Roche: Bitopertin was in-licensed from Roche in May 2021. Disc obtained global rights to develop and commercialize bitopertin, with Roche receiving milestone and royalty entitlements (financial structure not publicly disclosed in detail).

Pricing tiers

ModelBillingPrice
Other—Not applicable — pre-revenue, clinical-stage company with no approved products.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels8 records

Disc Medicine product offering

Product offering

Core offering

Disc Medicine is a clinical-stage biopharmaceutical company developing investigational therapies for hematologic diseases and rare blood disorders. The company's pipeline targets two core biological processes: heme biosynthesis modulation and hepcidin pathway modulation (both suppression and induction). Lead assets include bitopertin (oral GlyT1 inhibitor for EPP/XLP), DISC-0974 (anti-HJV antibody for anemia of inflammation), DISC-3405 (anti-TMPRSS6 antibody for iron overload disorders), and DISC-0998 (preclinical anti-HJV). The company is pre-revenue with no approved products on the market.

Product overview

Disc Medicine is a clinical-stage biopharmaceutical company developing therapeutics for hematologic diseases. No detailed product/module breakdown is supported by properly attributed source data.

Differentiator

Problem solved

Functional benefit

Products and services

  • Bitopertin Oral selective inhibitor of glycine transporter 1 (GlyT1) that limits glycine uptake into developing red blood cells, regulating downstream heme biosynthesis and reducing toxic protoporphyrin IX (PPIX) accumulation. In-licensed from Roche and being developed for EPP, XLP, and DBA. Currently in Phase 3 APOLLO trial (183 participants across US, Canada, Europe, Australia), with topline data expected Q4 2026 and potential FDA decision anticipated by mid-2027 following the February 2026 Complete Response Letter.
  • DISC-0974 Anti-hemojuvelin (HJV) monoclonal antibody that binds HJV to suppress hepcidin expression, enhancing iron availability for erythropoiesis to treat anemia of inflammation. In-licensed from AbbVie. Phase 2 RALLY-MF trial reported 70% overall response rate with 54-67% major response rates across evaluable cohorts in myelofibrosis patients.
  • DISC-3405 Recombinant humanized monoclonal antibody targeting TMPRSS6 (Matriptase-2) to induce endogenous hepcidin expression, reducing iron levels for diseases enabled by iron availability. Mechanism validated by human genetics (IRIDA patients with TMPRSS6 mutations). In-licensed from Mabwell. Holds FDA Fast Track Designation for polycythemia vera (PV).
  • DISC-0998
  • Bitopertin Expanded Access Program (EAP) Expanded Access Program providing investigational bitopertin to eligible EPP/XLP patients who lack satisfactory therapeutic alternatives. Listed on ClinicalTrials.gov (NCT07603401) and accessible via bitopertinEAP@discmedicine.com. Functions as the current pre-approval access pathway for the lead asset.

Quantifiable outcome

  • 55-64% major response rates in myelofibrosis patients across subgroups in DISC-0974 RALLY-MF Phase 2 trial
  • +3 more outcomes

Companies that use Disc Medicine

Customer profile

Named customers2 records

Ideal customer profiles2 records

Disc Medicine technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Disc Medicine partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and flagship.

  • Gemini TherapeuticscoreStrategic or Co-development Partner · 10 August 2022Gemini Therapeutics announced plans to merge with Disc Medicine in August 2022, as part of Gemini's strategic restructuring efforts. The merger brought together Gemini's ocular/age-related macular degeneration program with Disc's hematology pipeline; Georges Gemayel (former Executive Chair of Gemini Therapeutics) now serves on Disc Medicine's Board of Directors.
  • RocheflagshipOEM/ Whitelabel/ Licensing Partner · 1 May 2021Bitopertin (GlyT1 inhibitor) was in-licensed from Roche in May 2021, with Disc obtaining global rights to develop and commercialize the asset for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) and other conditions associated with abnormal erythropoiesis. Bitopertin was previously studied in over 4,000 participants across other indications, providing extensive safety characterization.
  • AbbVieflagshipOEM/ Whitelabel/ Licensing PartnerDISC-0974 (anti-hemojuvelin monoclonal antibody for anemia of inflammation) and DISC-0998 (extended half-life anti-HJV antibody) were in-licensed from AbbVie. Disc has advanced DISC-0974 into multiple Phase 1b/2 and Phase 2 studies in myelofibrosis, inflammatory bowel disease, and chronic kidney disease.
  • Mabwell TherapeuticsflagshipOEM/ Whitelabel/ Licensing PartnerDISC-3405 (anti-TMPRSS6 monoclonal antibody, formerly MWTX-003) was in-licensed from Mabwell Therapeutics. Mabwell (Shanghai) Bioscience Co., Ltd. holds international licensing partnership with Disc worth up to US$412.5 million. Phase 1 healthy volunteer study completed; Phase 2 PV (FDA Fast Track) and Phase 1b SCD studies initiated.
  • National Institutes of Health (NIH)coreStrategic or Co-development PartnerInvestigator-initiated trial with NIH for bitopertin in Diamond Blackfan Anemia (DBA), a rare congenital bone marrow failure syndrome. This is a Phase 2 study leveraging the bitopertin mechanism for heme modulation in a second indication.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Disc Medicine competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Disc Medicine social profiles

Digital presence

Disc Medicine financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Disc Medicine leadership team

Management profile

Number of profiles

Profiles15 records

Disc Medicine funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors20 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Disc Medicine M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Disc Medicine

What does Disc Medicine do?

Disc Medicine is a clinical-stage biopharmaceutical company developing investigational therapies for hematologic diseases and rare blood disorders. The company's pipeline targets two core biological processes: heme biosynthesis modulation and hepcidin pathway modulation (both suppression and induction). Lead assets include bitopertin (oral GlyT1 inhibitor for EPP/XLP), DISC-0974 (anti-HJV antibody for anemia of inflammation), DISC-3405 (anti-TMPRSS6 antibody for iron overload disorders), and DISC-0998 (preclinical anti-HJV). The company is pre-revenue with no approved products on the market.

Is Disc Medicine a public or private company?

Disc Medicine is a public company. It is classified as public and is currently operating.

When was Disc Medicine founded?

Disc Medicine was founded in 2022. It employs 101 to 250 people.

Where is Disc Medicine based?

Disc Medicine is headquartered in Watertown, United States, in the North America region.

How does Disc Medicine make money?

Three revenue lines are on record. Pre-Revenue / Clinical Stage is the primary driver. The others are future Drug Commercialization (Planned) and bitopertin In-Licensing from Roche.

Does Disc Medicine have an API?

No public API is recorded for Disc Medicine.

What industry is Disc Medicine in?

Disc Medicine's product category is Rare Hematology Biopharmaceuticals. Its primary akta.pro industry code is HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO, with a secondary code of HLAIAIAC, Rare Oncology & Hematologic Malignancy Therapies. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Seeking AlphaDisc Medicine, Inc. (IRON) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks TranscriptDisc Medicine's CEO John Quisel presented at the UBS Global Biopharma Conference, detailing its three clinical-stage programs targeting red blood cell disorders. The lead program, bitopertin, achieved a successful Phase III readout in erythropoietic protoporphyria, with two other programs in Phase II progressing toward Phase III.American Banking and Market NewsDisc Medicine, Inc. $IRON Shares Purchased by Aberdeen Group plcAberdeen Group plc increased its stake in Disc Medicine by 36.4% in Q3, holding 597,841 shares worth $39.1 million. Several other funds also adjusted positions, while insiders sold 150,277 shares in 90 days. Analysts rate the stock a Moderate Buy with a $124.18 price target.Simply Wall StHow Investors Are Reacting To Disc Medicine (IRON) Narrower Quarterly LossDisc Medicine reported Q3 2026 net loss of $59.54 million and basic loss per share of $1.53, with nine-month loss of $182.57 million. The company's late-stage hematology pipeline requires future regulatory and commercial milestones to offset cash burn. The planned resubmission of the bitopertin application by end of 2026 is the key near-term catalyst.BNNHot Picks: Three U.S. biotech stocks to watchWedbush analyst David Nierengarten discussed Scholar Rock, Disc Medicine, and Hemab Therapeutics, focusing on rare disease treatments. Scholar Rock's Isembyld launch faces infusion scheduling delays, Disc Medicine's bitopertin expects FDA decision by mid-2027, and Hemab's Phase 3 SOLARA trial for Glanzmann thrombasthenia is underway.Defense WorldDisc Medicine, Inc. $IRON Holdings Raised by Alps Advisors Inc.Alps Advisors increased its stake in Disc Medicine by 31.9% in Q3, buying 12,291 shares. Insiders sold 168,046 shares in the quarter, while analysts raised price targets with a consensus of $124.18. The company reported a loss of $1.53 per share, beating estimates.American Banking and Market NewsDisc Medicine, Inc. $IRON Stock: Alps Advisors Inc. Increases PositionAlps Advisors increased its stake in Disc Medicine by 31.9% in Q3, holding 50,856 shares worth $3.33 million. Other institutional investors also adjusted positions, with Opaleye Management owning 855,000 shares. Analysts rate the stock a Moderate Buy with an average price target of $124.18.Dealroom.coDisc Medicine raises $486M after bitopertin Phase 3 winDisc Medicine raised $485.9 million in an October public offering after its lead drug bitopertin met all primary and secondary endpoints in the Phase 3 APOLLO trial for erythropoietic protoporphyria. The company plans to resubmit its New Drug Application by year-end, with an FDA decision expected by mid-2027.Simply Wall StWhat Disc Medicine (IRON)'s Phase 3 Trial Success Means For ShareholdersDisc Medicine reported a Q3 2026 net loss of US$59.54 million and confirmed its Phase 3 APOLLO trial of bitopertin met all primary and secondary endpoints. The company plans to resubmit the bitopertin NDA by end of 2026, targeting an FDA decision in mid-2027. The result improves regulatory prospects but the firm remains loss-making and unprofitable for several years.Simply Wall StDisc Medicine (IRON) Nails Phase 3 APOLLO Readout, Is The 34% Undervaluation Still Real?Disc Medicine's Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria met all primary and secondary endpoints. The company's fair value is estimated at $125.75 per share versus a last close of $83.28, implying a 34% undervaluation. Further FDA delays or slower real-world uptake could break the bullish script.Quiver QuantitativeDISC MEDICINE ($IRON) Releases Q3 2026 Earnings | IRON Stock NewsDISC MEDICINE reported Q3 2026 earnings of -$1.53 per share, beating estimates of -$1.76, with revenue of $0. Insiders sold 48 times in six months, and hedge fund activity shows 118 adding and 84 reducing positions. Analysts have set a median price target of $86.5.